Lanean...
Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma
BACKGROUND: To evaluate the efficacy and safety of everolimus, a mTOR inhibitor, on invasive malignant renal epithelioid angiomyolipoma (EAML). MATERIALS AND METHODS: From Oct 2014 to May 2019, we collected data from seven patients with a definite (clinical and pathological) diagnosis of EAML receiv...
Gorde:
| Argitaratua izan da: | Front Oncol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Frontiers Media S.A.
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7870865/ https://ncbi.nlm.nih.gov/pubmed/33575217 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.610858 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|